

### Study Identification

First Author: Study Name:	Year:
Language (if not English): Geographic location:	Single or Multi-center:
Funding Source Specify: <input type="checkbox"/> Industry <input type="checkbox"/> Government/Foundation <input type="checkbox"/> Academia <input type="checkbox"/> Other/Unknown	Publication form: <input type="checkbox"/> Full-text <input type="checkbox"/> Abstract <input type="checkbox"/> Other (specify):

### Design Characteristics

Study Design <input type="checkbox"/> RCT <input type="checkbox"/> Observational
Random Allocation Concealment?   Y   N      Blinded Outcome Assessment?   Y   N      Intention to treat principle used?   Y   N

### Study Population

**Inclusion Criteria:**

- |  |  |
|--|--|
| <input type="checkbox"/> Native vessel                           | <input type="checkbox"/> TIMI 0/1  |
| <input type="checkbox"/> Acute MI within ___ hrs                 | <input type="checkbox"/> Time from symptom onset:                                  |
| <input type="checkbox"/> Angiographically visible thrombus       | <input type="checkbox"/> Age ≥ 18 years  |
| <input type="checkbox"/> Chest pain associated with ACS > ___min | <input type="checkbox"/> ST-segment elevation ≥ 0.1mV (1mm) in 2 or more ECG leads |

**Exclusion Criteria:**

- |  |   |
|--|---|
| <input type="checkbox"/> Saphenous vein grafts                 | <input type="checkbox"/> Cardiac tamponade      |
| <input type="checkbox"/> Contraindication to GP 2B3A Inhibitor | <input type="checkbox"/> Aortic dissection      |
| <input type="checkbox"/> Cardiogenic shock                     | <input type="checkbox"/> Myocarditis            |
| <input type="checkbox"/> Left- BBB                             | <input type="checkbox"/> Renal Failure          |
| <input type="checkbox"/> Ventricular pacing at baseline        | <input type="checkbox"/> Pregnancy              |
| <input type="checkbox"/> Previous MI in past ___days           | <input type="checkbox"/> Fibrinolytic treatment |
| <input type="checkbox"/> Inability to obtain informed consent  |   |
| <input type="checkbox"/> Previous Coronary Bypass surgery      |   |
| <input type="checkbox"/> Killip class IV                       |   |
| <input type="checkbox"/> Ventricular Tachycardia               |   |

Device name:

Device category:

- |   |   |
|---|---|
| <input type="checkbox"/> Catheter Aspiration (Export, TVAC, Rescue, Pronto, Diver CE) | <input type="checkbox"/> Mechanical Thrombectomy (Angiojet, X-Sizer)                        |
| <input type="checkbox"/> Balloon Distal Embolic Protection (Guardwire)                | <input type="checkbox"/> Filter Distal Embolic Protection (Filterwire, SpiderX, Angioguard) |
| <input type="checkbox"/> Proximal Embolic Balloon Protection                          | <input type="checkbox"/> Proximal Embolic Filter Protection                                 |

Follow-Up Months (study) :

Follow-Up for primary outcome, n/N (%):

Define primary outcome:

**Device Group**

**Control Group**

--

--

**Baseline Characteristics**

		Device Group	Control Group				Device Group	Control Group
N					Dyslipidemia, n/N (%)			
Age, years (mean± SD)					Hypertension n/N (%)			
Males, n/N (%)					Baseline TIMI 0-1 Flow, n/N (%) or mean ± SD, specify			
Anterior MI n/N (%)					DM n/N (%)			
Family history of CAD n/N (%)					Smoker n/N (%)			
Prior Myocardial Infarction n/N (%)					Failed TL n/N (%)			
Mean Ischemic Time, min (mean± SD or median±IQR, specify) Definition:					Killip Class n/N (%) Definition:			
Definition:					Thrombus Score n/N (%) Definition:			
		Device Group	Control Group				Device Group	Control Group
ACS n/N (%)	STEMI				Infarct Related Artery n/N (%)	LAD Lesion		
	N-STEMI					LCX Lesion		
	Unstable Angina					RCA Lesion		
						Other:		

Multi-vessel Disease n/N (%) Definition:				Visible lesion on angiography n/N (%) Definition:		
Pre-cTFC (mean± SD)				Pre-LVEF (mean± SD)		
Ethnicity reported?						

### Concurrent Drugs Used

<b>Anti-platelet Therapy</b>				
<input type="checkbox"/> Aspirin Regimen:	<input type="checkbox"/> Ticlopidine: Regimen:	<input type="checkbox"/> Clopidogrel Regimen:	<input type="checkbox"/> GP2B3A Regimen:	<input type="checkbox"/> Other Regimen:
<b>Antithrombotic Therapy</b>				
<input type="checkbox"/> Heparin Regimen:	<input type="checkbox"/> Others Regimen:	ACT (or other monitoring parameter, please specify):		
<b>Vasodilators</b>				
<input type="checkbox"/> Nitrates Regimen:	<input type="checkbox"/> Nitroglycerine Regimen:	<input type="checkbox"/> Others Regimen:		

### Procedural Characteristics

		Device Group	Control Group
Procedural Time (min) mean± SD or median±IQR, specify	Definition:		
Stent n/N (%)			
Direct Stent n/N (%)			
Need of IABP n/N (%)			
Need of pacing n/N (%)			
Emergency CABG n/N (%)			
GP2B3A use n/N (%) Define use:			
Lesion debris removed from filter n/N (%)			

**Surrogate Outcomes**

	<b>Device Group</b>	<b>Control Group</b>
MBG n/N (%) Definition:		
Post-PCI TIMI 3 n/N (%)		
Post cTFC (mean % $\pm$ SD)		
LVEF (mean % $\pm$ SD)		
Distal embolization n/N (%)		
Infarct size (mean % $\pm$ SD)		
Procedural Success Rate n/N (%)		
No Reflow n/N (%)		
Slow Reflow n/N (%)		
CK-MB n/N (%) or mean $\pm$ SD Definition:		

**Safety Outcomes**

	<b>Device Group</b>	<b>Control Group</b>
Coronary Dissection n/N (%)		
Perforation n/N (%)		
Prolonged Procedure n/N (%)		
Other (please specify):		
Other (please specify):		

**ST-Segment Resolution**

<b>Post Procedure/immediate</b>					<b>60 Minutes</b>			
<b>STSR %</b>	<b>&lt;30%</b>	<b>30-70%</b>	<b>&gt;70%</b>	<b>Others</b>	<b>&lt;30%</b>	<b>30-70%</b>	<b>&gt;70%</b>	<b>Others</b>
<b>Device Group n/N (%)</b>								
<b>Control Group n/N (%)</b>								

<b>90 Minutes</b>					<b>Others</b>			
<b>STSR %</b>	<b>&lt;30%</b>	<b>30-70%</b>	<b>&gt;70%</b>	<b>Others</b>	<b>&lt;30%</b>	<b>30-70%</b>	<b>&gt;70%</b>	<b>Others</b>
<b>Device Group n/N (%)</b>								
<b>Control Group n/N (%)</b>								

**Other measures of ST resolution:**

**Final Health Outcomes**

Composite MACE or MACCE n/N (%)	Definition	Time Period	Device Group	Control Group
Other individual endpoints included in MACE or MACCE not listed below	Endpoint:			
Mortality n/N (%)	Definition			
TVR n/N (%)				
Reinfarction n/N (%)				
Stroke n/N (%)				